FindTrial
Sign In

To observe the comparison of efficacy of amroitinib combined with first-line chemotherapy and first-line chemotherapy alone in preoperative neoadjuvant therapy for stage IIIA non-small cell lung cancer

To observe the comparison of efficacy of amroitinib combined with first-line chemotherapy and first-line chemotherapy alone in preoperative neoadjuvant therapy for stage IIIA non-small cell lung cancer

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026631
Enrollment
Unknown
Registered
2019-10-16
Start date
2019-10-17
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Experimental group:The first line protocol + Anlotinib
Control group:The first line protocol

Sponsors

The Second People's Hospital of Yibin
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Stage IIIA non-small cell lung cancer patient; 2. ECOG 0, 1; 3. Expecting survival more than 6 months; 4. Liver function: total bilirubin =1.5 ULN or creatinine clearance rate >=50mL/min, and urinary protein =1g can be selected); 6. Within 7 days before treatment, the international standardized rate (INR) <=1.5, and partial prothrombin time (PTT or aPTT) <=1.5.

Exclusion criteria

Exclusion criteria: 1. Small-cell lung cancer (including mixed small-cell and non-small-cell cancers); 2. Central or hollow squamous cell carcinoma or accompanied by hemoptysis (> 50ml/d); 3. The tumor has obviously invaded important blood vessels; 4. Abnormal coagulation;5. Surgery cannot be tolerated with severe cardiopulmonary dysfunction.

Design outcomes

Primary

MeasureTime frame
PFS;—

Secondary

MeasureTime frame
Surgical resection rate;—

Countries

China

Contacts

Public ContactJia Yuming

Chinese Ethics Committee of Registering Clinical Trials

ybjqx3340@sina.com+86 13330663082

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026